BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38602878)

  • 21. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
    Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
    Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
    Vonderheide RH; Bear AS
    Front Immunol; 2020; 11():605619. PubMed ID: 33304355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
    He P; Yang JW; Yang VW; Bialkowska AB
    Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
    Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
    Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
    Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
    Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
    Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
    Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer.
    Kabashima A; Matsuo Y; Ito S; Akiyama Y; Ishii T; Shimada S; Masamune A; Tanabe M; Tanaka S
    Sci Rep; 2022 Jun; 12(1):10466. PubMed ID: 35773436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
    Helm O; Mennrich R; Petrick D; Goebel L; Freitag-Wolf S; Röder C; Kalthoff H; Röcken C; Sipos B; Kabelitz D; Schäfer H; Oberg HH; Wesch D; Sebens S
    PLoS One; 2014; 9(5):e94357. PubMed ID: 24797069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer.
    Quaranta V; Rainer C; Nielsen SR; Raymant ML; Ahmed MS; Engle DD; Taylor A; Murray T; Campbell F; Palmer DH; Tuveson DA; Mielgo A; Schmid MC
    Cancer Res; 2018 Aug; 78(15):4253-4269. PubMed ID: 29789416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 37. KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages.
    Li MX; Wang HY; Yuan CH; Ma ZL; Jiang B; Li L; Zhang L; Xiu DR
    Clin Sci (Lond); 2021 Feb; 135(4):629-649. PubMed ID: 33538300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
    Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
    Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.